Barclays PLC grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 26.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 239,836 shares of the biopharmaceutical company’s stock after acquiring an additional 50,307 shares during the quarter. Barclays PLC owned 0.25% of Intra-Cellular Therapies worth $12,988,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of Intra-Cellular Therapies by 11.7% during the 1st quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock worth $9,615,000 after purchasing an additional 16,454 shares during the period. Bank of New York Mellon Corp raised its stake in Intra-Cellular Therapies by 5.2% in the 1st quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock valued at $23,591,000 after acquiring an additional 18,999 shares during the period. Cambridge Investment Research Advisors Inc. bought a new stake in Intra-Cellular Therapies in the 1st quarter valued at about $349,000. PNC Financial Services Group Inc. raised its stake in Intra-Cellular Therapies by 25.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 1,204 shares during the period. Finally, Natixis Advisors L.P. raised its stake in Intra-Cellular Therapies by 71.3% in the 1st quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock valued at $1,112,000 after acquiring an additional 7,558 shares during the period. 85.70% of the stock is owned by hedge funds and other institutional investors.
Intra-Cellular Therapies Price Performance
Shares of NASDAQ ITCI opened at $58.91 on Tuesday. Intra-Cellular Therapies, Inc. has a 12 month low of $42.01 and a 12 month high of $67.05. The business has a 50-day moving average of $62.66 and a 200-day moving average of $57.01.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on ITCI shares. Needham & Company LLC restated a “buy” rating and issued a $73.00 price objective on shares of Intra-Cellular Therapies in a research note on Thursday, August 3rd. StockNews.com upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Monday. Cantor Fitzgerald boosted their price objective on Intra-Cellular Therapies from $90.00 to $98.00 in a research note on Friday. Mizuho boosted their price objective on Intra-Cellular Therapies from $74.00 to $76.00 in a research note on Monday, May 8th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $80.00 price target on shares of Intra-Cellular Therapies in a research report on Friday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $75.80.
Get Our Latest Research Report on ITCI
Insiders Place Their Bets
In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 81,854 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $63.97, for a total value of $5,236,200.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Suresh K. Durgam sold 1,842 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $65.00, for a total transaction of $119,730.00. Following the completion of the sale, the executive vice president now owns 21,262 shares of the company’s stock, valued at $1,382,030. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Lawrence J. Hineline sold 81,854 shares of the stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $63.97, for a total value of $5,236,200.38. The disclosure for this sale can be found here. 3.40% of the stock is owned by insiders.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Read More
- Five stocks we like better than Intra-Cellular Therapies
- What Are Dividends? Buy the Best Dividend Stocks
- 8 Best Meme Stocks to Buy Now
- Trading Stocks: RSI and Why it’s Useful
- Is Now The Time To Buy XLF Financial ETF?
- Why Average Daily Trading Volume Matters to Every Investor
- Three Ways To Play The Rise In Oil Prices
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
